Moderate‐potency vs mild‐potency topical corticosteroid
Local adverse events: skin thinning; end of treatment (2‐5 weeks) · children and adults with mild to severe eczema
Moderate‐potency may leads to lower local adverse events: skin thinning; end of treatment (2‐5 weeks) compared with mild‐potency topical corticosteroid (low certainty).
1 finding from 1 review
- Strategies for using topical corticosteroids in children and adults with eczema 2022 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 472 participantsLow